More Lebed:
The PSA test has $450 million in annual revenues worldwide.
The PSA test only detects 40-60% of prostate cancers with many false positives.
BOCX's RECAF test was just proven to detect twice the cancers that the PSA would have detected.
Therefore, shouldn't BOCX be worth at least $450 million?
More importantly, BOCX's RECAF has also been proven effective at detecting 90% of lung cancers. This is now the start of National Lung Cancer Awareness Month. A new 10-year study just released showed that annual CT scans detected lung cancer early and brought 10-year survivals rates up to 90%.
BOCX's RECAF is much easier and cheaper to use than CT scans. With all of the attention this CT scan study has gotten and with BOCX going to be featured on National Television this weekend, I can't imagine what kind of media attention BOCX is about to receive.
When you factor in the potential market for detecting lung, breast and other cancers, BOCX could easily become a billion dollar company.
BOCX only has 36.7 million shares outstanding. At $0.86 we have a $32 million company with the potential to be worth $1 billion. This makes me believe BOCX is at the ground-floor right now.
Look at the volume BOCX is starting to trade. Look at the media attention BOCX will receive in the upcoming days. This thing is ready to explode.
Commercialization is just around the corner!!!
-----
My firm Lebed Biz LLC has been compensated by a third-party (Onyx Consulting), $25,000 cash for a one-month BOCX investor relations contract. Never invest into a stock we discuss unless you can afford to lose your entire investment. For our full disclaimer go to: www.lebed.biz/disclaimer.htm
Jonathan Lebed
Lebed.biz
Staff
